OTM recognised as the Leading Travel Trade Show in India and Asia, for the Second Year in a Row, in a custom study commissioned by Fairfest Media and conducted by NielsenIQ
MUMBAI, India, May 30, 2025 /PRNewswire/ -- OTM has once again been recognized as the leading travel trade show in both India and Asia, according to a comprehensive custom market research study commissioned by Fairfest Media and conducted by NielsenIQ, the leader in consumer intelligence. This recognition, for the second consecutive year, underscores OTM's continued leadership in the travel exhibition landscape. The latest study, conducted among travel industry professionals who attended multiple travel shows in 2025, revealed even higher satisfaction scores and stronger performance metrics compared to the previous year, with OTM decisively outperforming other major shows across the region.
The comprehensive custom survey, commissioned by Fairfest Media, evaluated 15 international travel trade shows across Asia and 19 regional shows in India. The study found a 'significantly higher quantum of respondents stating OTM to be the leading show at a National & Asia level', outperforming other major shows, including ITB Asia and SATTE.
Overwhelming Industry Recognition
The extensive 2025 study revealed:
Among professionals who participated in or visited 2 or more shows in India, 55% recognised OTM as the leading national show
Among those who attended multiple shows in Asia, 52% ranked OTM as the top show across Asia
OTM has played a crucial role in major business transactions, with the majority of the attendees saying they made purchase decisions within 3 months of attending the event.
Mr. Sanjiv Agarwal, Chairman & CEO of Fairfest Media, commented: "At Fairfest Media, we're deeply committed to delivering measurable ROI for our exhibitors and visitors, which is why we commissioned this comprehensive custom study conducted by NielsenIQ. The consecutive recognition of OTM in the study confirms that OTM continues to set the standard for the industry, in India and globally. As we prepare for OTM 2026, we remain focused on further enhancing the experience and business outcomes for all participants."
Future Growth Opportunities
The study also identified expansion opportunities that will guide OTM's future development:
Travel professionals expressed interest in seeing increased representation from the Americas (particularly USA and Brazil), Europe (with emphasis on Switzerland and the Nordic countries), and Asia (especially Singapore and Turkey).
Enhanced conference programming has been identified as an opportunity area for future development.
The comprehensive custom survey evaluated travel trade shows across Asia and regional shows in India. Countries covered in the customized study (conducted by NielsenIQ and commissioned by Fairfest Media) included India, Singapore, Egypt, Sri Lanka, United Kingdom, Maldives, Tanzania, Greece, Philippines, Russia, Netherlands, Vietnam & Republic of Korea.
The population covered in the study includes exhibitors and visitors of travel trade shows. The total usable database of visitors shared with NielsenIQ by Fairfest Media was over 32,000, and of exhibitors was over 2,832. The sample size was overall (N=211); exhibitors (N=56), and visitors (N=155). The sampling method was online, purposive sampling.
The next edition of OTM is scheduled for 5, 6 & 7 February 2026 at the Jio World Convention Centre in Mumbai. Based on current projections and the strong satisfaction metrics from the 2025 event, OTM 2026 is expected to further strengthen its lead in both the country and the region.
About OTM and Fairfest Media Limited
OTM, organised by Fairfest Media Limited, is the leading travel trade show in Asia and India. Each year, it brings together a global network of exhibitors, buyers, and travel industry professionals to connect, showcase innovations, and generate business opportunities. Fairfest Media also organises TTF-branded travel shows in 7 Indian cities, making it the largest travel trade show organiser in India. As the leading travel show organiser in the region, Fairfest continues to shape the future of travel in the world's fastest-growing market.
About NIQ
NielsenIQ (NIQ) is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behaviour and revealing new pathways to growth. NIQ combined with GfK in 2023, bringing together two industry leaders with unparalleled global reach. Our global reach spans over 90 countries, covering approximately 85% of the world's population and more than $7.2 trillion in global consumer spend. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™. For more information, please visit www.niq.com
Media Contact
Sandrine Clarac Director - Marketing and International Sales Fairfest Media LimitedPhone: +91-2245558555
Photo: https://mma.prnewswire.com/media/2698957/FAIRFEST_OTM_Jio_World.jpg
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/otm-recognised-as-the-leading-travel-trade-show-in-india-and-asia-for-the-second-year-in-a-row-in-a-custom-study-commissioned-by-fairfest-media-and-conducted-by-nielseniq-302468497.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Danske Bank AS (DNKEY) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth
Net Profit: DKK11.2 billion for the first half of 2025, down 2% year on year. Return on Shareholders' Equity: 13% for the first half of 2025. Lending Growth: Up 5% compared to last year. Deposit Growth: Increased by 3% in the first half of 2025. Cost-to-Income Ratio: 45.4%, progressing towards 2026 targets. Net Interest Income (NII): Stable year-on-year and quarter-on-quarter. Fee Income: Down 7% in Q2 compared to Q1, but stable year-on-year. Trading Income: Increased 26% from the same period last year. Operating Expenses: In line with full-year guidance of up to DKK26 billion. Loan Impairment Charges: DKK0.3 billion for the first half, below full-year guidance of DKK1 billion. CET1 Ratio: Increased to 18.7% at the end of Q2 2025. Assets Under Management (AUM): Grew 3% in Q2 relative to the preceding quarter. Warning! GuruFocus has detected 6 Warning Sign with DNKEY. Release Date: July 18, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Danske Bank AS (DNKEY) reported a net profit of DKK11.2 billion, achieving a return on shareholders' equity of 13%, which aligns with their financial targets for 2026. The bank experienced a 5% increase in lending, particularly driven by corporate customers, contributing to an improved market share for corporate lending across all Nordic countries. Deposits grew by 3% in the first half of 2025, with significant contributions from large corporate and retail business sectors. The bank's strategic focus on expanding its cash management business and investing in technology aligns with its FORWARD 28 strategy, supporting long-term growth. Credit quality remained strong, with loan impairment charges well below the cycle, maintaining a positive outlook for the full year. Negative Points Net profit was down 2% year-on-year, primarily due to lower net income from the insurance business and higher loan impairment charges. Fee income was softer than expected, impacted by reduced investment activity and lower refinancing activity in the mortgage sector. Operating expenses remained stable, but there was a slight increase in costs related to financial crime prevention. The macroeconomic environment, despite being generally favorable, still posed challenges with geopolitical uncertainties affecting consumer and business sentiment. The bank's net interest income (NII) faced pressure from rate cuts, although partially mitigated by increased volumes and structural hedging. Q & A Highlights Q: The fee income was relatively soft this quarter. How should we think about the fee income for the coming quarters? Do you see scope for recovery in asset management activity or advisory in the second half of the year? A: Carsten Rasch Egeriis, CEO: The fee income was softer than expected, mainly due to investment side challenges in April and lower lending fees from refinancing activities. However, AUMs ended at a record high, and we see good momentum on the investment side. We expect more activity in capital markets in the second half, with a solid pipeline, especially in advisory and capital market fees. Q: Can you remind us of your latest thoughts on capital allocation, particularly regarding dividends, buybacks, or M&A? A: Carsten Rasch Egeriis, CEO: We continue to generate healthy capital with a strong CET1 ratio of 18.7%. Our focus remains on distributing in-year earnings, and we will update our capital distribution strategy in Q1 next year. Our priority is to grow our business, and we will consider potential capital distribution if growth does not meet expectations. Q: On your guidance, the numbers are the same, but it seems there's a shift towards higher NII and lower fees. Is that fair? A: Carsten Rasch Egeriis, CEO: Yes, we adjusted the guidance wording due to weaker Q2 fees. Despite this, we remain positive about our strategy and fee opportunities. We continue to feel good about the NII trajectory, expecting it to be above DKK35 billion, supported by strong volume growth and structural hedges. Q: Can you explain the increase in NII sensitivity for downward rate movements? A: Cecile Hillary, CFO: The sensitivity increase to minus DKK650 million for a 25 basis points decrease is due to approaching the zero bound, reducing our ability to pass rate changes to deposits. Additionally, minor changes in sensitivity for rate increases and adjustments in our deposit bond hedge contribute to this. Q: What are your views on the competitive dynamics in Denmark, especially with the CRR3 output floors not applying to Danish subsidiaries? A: Carsten Rasch Egeriis, CEO: We have already front-loaded the CRR3 impact, and I don't foresee changes in competitive dynamics. Historically, Denmark's early adoption created some unlevel playing fields, but we've navigated through it. We continue to monitor regulatory developments, especially concerning European competitiveness and simplification. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Getinge AB (GNGBF) Q2 2025 Earnings Call Highlights: Strong Organic Growth and Margin ...
Organic Net Sales Growth: 4.1% in Q2 2025. Order Intake Growth: 4.4% organically. Recurring Revenue: 65% of total sales. High Margin Products: Comprise about 2/3 of sales. Adjusted Gross Profit: SEK4.183 billion. Gross Margin Increase: Up by 0.8 percentage points. Adjusted EBITDA: SEK989 million, margin improved by 0.2 percentage points to 12%. Tariff Costs: Approximately SEK110 million in Q2. Free Cash Flow: SEK0.5 billion in Q2. Net Debt: SEK11.7 billion, leverage at 1.7 times adjusted EBITDA. Cash Position: Approximately SEK1.9 billion at the end of Q2. 2025 Outlook: Organic net sales growth expected to be 2% to 5%. Warning! GuruFocus has detected 6 Warning Signs with GNGBF. Release Date: July 18, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Getinge AB (GNGBF) reported a solid quarter with net sales growing by 4.1% organically, driven by positive development across all business areas and regions. The company achieved a significant increase in sales from recurring revenue, now at 65%, and high-margin products make up about two-thirds of sales. Adjusted gross and EBITDA margins improved due to acquisitions, healthy price increases, and a positive mix, despite tariffs and currency headwinds. The financial position remains strong with financial leverage well below 2.5 times EBITDA, even after the acquisition of Paragonix. Getinge AB (GNGBF) continues to invest in new products and solutions, such as the Servo-c ventilator with neonatal options and the Zen disinfection chemistry portfolio, enhancing its market offerings. Negative Points Tariffs and currency fluctuations negatively impacted the EBITDA margin, with tariffs costing approximately SEK110 million in the second quarter. The Life Science segment experienced softer performance due to high comparative figures from the previous year. There are ongoing elevated costs related to quality improvements, particularly in the balloon pump and cardiopulmonary categories. The company faces challenges in maintaining market share in certain categories, such as intra-aortic balloon pumps, due to restrictions on actively selling and marketing these products. Despite positive trends, the company anticipates more difficult comparisons in the second half of the year, particularly in ventilator sales. Q & A Highlights Q: Can you explain the implications of tariffs and FX on your long-term guidance and whether you've found new mitigation strategies? A: Our long-term guidance is based on the current tariff situation. We haven't found new mitigation strategies but are utilizing existing productivity improvements and regional supply chain strategies. The impact of tariffs and FX is significant, but we are managing it within our existing frameworks. - Mattias Perjos, CEO Q: What are your current assumptions regarding EU tariffs, and how do you expect them to impact your full-year results? A: We currently assume a 10% EU tariff for the full year. If tariffs increase, we would need to recalibrate our calculations. We don't provide specific guidance on future tariffs or FX impacts. - Agneta Palmer, CFO Q: How is the demand for ventilators expected to evolve, and can you disclose the number of ventilators you anticipate selling this year? A: Ventilator demand remains strong, but we expect more challenging comparisons in the second half of the year. We do not disclose specific sales numbers for ventilators. - Mattias Perjos, CEO Q: Could you provide more details on the tariff payments and their regional impact? A: Tariff payments began in the second half of April, primarily affecting EU to US flows. We have taken measures to manage our supply chain in response to these tariffs. - Agneta Palmer, CFO Q: What is driving the positive development of Paragonix, and can you provide any margin details? A: The margin expansion for Paragonix is volume-driven, and it is now accretive to group margins. The growth is supported by a successful product portfolio, including the KidneyVault launch. - Mattias Perjos, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Inicia sesión para acceder a tu portafolio
Yahoo
a day ago
- Yahoo
Getinge AB (GNGBF) Q2 2025 Earnings Call Highlights: Strong Organic Growth and Margin ...
Organic Net Sales Growth: 4.1% in Q2 2025. Order Intake Growth: 4.4% organically. Recurring Revenue: 65% of total sales. High Margin Products: Comprise about 2/3 of sales. Adjusted Gross Profit: SEK4.183 billion. Gross Margin Increase: Up by 0.8 percentage points. Adjusted EBITDA: SEK989 million, margin improved by 0.2 percentage points to 12%. Tariff Costs: Approximately SEK110 million in Q2. Free Cash Flow: SEK0.5 billion in Q2. Net Debt: SEK11.7 billion, leverage at 1.7 times adjusted EBITDA. Cash Position: Approximately SEK1.9 billion at the end of Q2. 2025 Outlook: Organic net sales growth expected to be 2% to 5%. Warning! GuruFocus has detected 6 Warning Signs with GNGBF. Release Date: July 18, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Getinge AB (GNGBF) reported a solid quarter with net sales growing by 4.1% organically, driven by positive development across all business areas and regions. The company achieved a significant increase in sales from recurring revenue, now at 65%, and high-margin products make up about two-thirds of sales. Adjusted gross and EBITDA margins improved due to acquisitions, healthy price increases, and a positive mix, despite tariffs and currency headwinds. The financial position remains strong with financial leverage well below 2.5 times EBITDA, even after the acquisition of Paragonix. Getinge AB (GNGBF) continues to invest in new products and solutions, such as the Servo-c ventilator with neonatal options and the Zen disinfection chemistry portfolio, enhancing its market offerings. Negative Points Tariffs and currency fluctuations negatively impacted the EBITDA margin, with tariffs costing approximately SEK110 million in the second quarter. The Life Science segment experienced softer performance due to high comparative figures from the previous year. There are ongoing elevated costs related to quality improvements, particularly in the balloon pump and cardiopulmonary categories. The company faces challenges in maintaining market share in certain categories, such as intra-aortic balloon pumps, due to restrictions on actively selling and marketing these products. Despite positive trends, the company anticipates more difficult comparisons in the second half of the year, particularly in ventilator sales. Q & A Highlights Q: Can you explain the implications of tariffs and FX on your long-term guidance and whether you've found new mitigation strategies? A: Our long-term guidance is based on the current tariff situation. We haven't found new mitigation strategies but are utilizing existing productivity improvements and regional supply chain strategies. The impact of tariffs and FX is significant, but we are managing it within our existing frameworks. - Mattias Perjos, CEO Q: What are your current assumptions regarding EU tariffs, and how do you expect them to impact your full-year results? A: We currently assume a 10% EU tariff for the full year. If tariffs increase, we would need to recalibrate our calculations. We don't provide specific guidance on future tariffs or FX impacts. - Agneta Palmer, CFO Q: How is the demand for ventilators expected to evolve, and can you disclose the number of ventilators you anticipate selling this year? A: Ventilator demand remains strong, but we expect more challenging comparisons in the second half of the year. We do not disclose specific sales numbers for ventilators. - Mattias Perjos, CEO Q: Could you provide more details on the tariff payments and their regional impact? A: Tariff payments began in the second half of April, primarily affecting EU to US flows. We have taken measures to manage our supply chain in response to these tariffs. - Agneta Palmer, CFO Q: What is driving the positive development of Paragonix, and can you provide any margin details? A: The margin expansion for Paragonix is volume-driven, and it is now accretive to group margins. The growth is supported by a successful product portfolio, including the KidneyVault launch. - Mattias Perjos, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
